Abstract
Background
Major BCR-ABL1 mRNA in patients with chronic myeloid leukemia (CML) has generally been analysed by real-time polymerase chain reaction (PCR). Application of the international scale (IS) for the quantification of major BCR-ABL1 mRNA has been recommended in several sets of guidelines, including those of the European LeukemiaNet. The aim of this study was to clarify the efficacy of digital PCR technology for the IS of BCR-ABL1 mRNA in the patients with CML by comparing with real-time PCR.
Methods
The analysis of BCR-ABL1 mRNA was carried out by the Ipsogen® BCR-ABL1 Mbcr IS-MMR DX Kit (Qiagen), and the QuantStudio 3D Digital PCR System (Thermo Fisher Scientific) using 20 peripheral blood samples obtained from the 9 patients with CML at Sapporo Medical University Hospital.
Results
The correlation between the data obtained by digital PCR and by real-time PCR was really high at R = 0.96. The detection limit of digital PCR was up to 0.003% and was equal to IS with 0.01% or less in comparison with real-time PCR.
Conclusions
Digital PCR technology is promising for predicting the IS value with similar efficacy to real-time PCR and should be useful for simple monitoring of the effects of tyrosine kinase inhibitor (TKI) treatments.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10147-019-01419-9/MediaObjects/10147_2019_1419_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10147-019-01419-9/MediaObjects/10147_2019_1419_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10147-019-01419-9/MediaObjects/10147_2019_1419_Fig3_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10147-019-01419-9/MediaObjects/10147_2019_1419_Fig4_HTML.png)
Similar content being viewed by others
References
Gabert J, Beillard E, van der Velden VH et al (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17:2318–2357
Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28–37
Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884
National Comprehensive Cancer Network (NCCN) (2016) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic Myelogenous Leukemia. Version 1. http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed 24 May 2017
Usui N (2017) JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol 106:591–611
Cross NC, Hochhaus A, Müller MC (2015) Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol 94:S219–S225
Hindson CM, Chevillet JR, Briggs HA et al (2013) Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 10:1003–1005
Koizumi Y, Furuya D, Endo T et al (2018) Quantification of Wilms’ tumor 1 mRNA by digital polymerase chain reaction. Int J Hematol 107:230–234
Goh HG, Lin M, Fukushima T et al (2011) Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma 52:896–904
Jennings LJ, George D, Czech J et al (2014) Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn 16:174–179
Iacobucci I, Lonetti A, Venturi C et al (2014) Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leuk Res 38:581–585
Alikian M, Whale AS, Akiki S et al (2017) RT-qPCR and RT-digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia. Clin Chem 63:525–531
Whelan JA, Russel NB, Whelan MA (2003) A method for the absolute quantification of cDNA using real time PCR. J Immunol Methods 278:261–269
Soverini S, De Benedittis C, Mancini M et al (2016) Best practices in chronic myeloid leukemia monitoring and management. Oncologist 21:626–633
Takahashi N, Tauchi T, Kitamura K et al (2018) Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol 107:185–193
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Furuya, D., Moriai, M., Koizumi, Y. et al. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale. Int J Clin Oncol 24, 871–875 (2019). https://doi.org/10.1007/s10147-019-01419-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-019-01419-9